BostonGene to Participate in the European Federation of Laboratory Medicine Strategic Conference 2024
BostonGene a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced today its participation in the European Federation of Laboratory Medicine (EFLM) Strategic Conference 2024, to be held in Padua, Italy, from September 23 to 24. The event, titled "A Vision to the Future: Value-Based Laboratory Medicine," will focus on shaping the future of laboratory medicine through innovative value-based approaches and integrated diagnostics.
Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene and Chair of the EFLM Integrated Diagnostics Task Group, will deliver a keynote presentation on Monday, September 23, from 2:30 PM to 3:00 PM. His keynote session, "Integrated Diagnostics," will explore how disease-specific diagnostic pathways can improve patient outcomes, reduce healthcare costs and optimize service delivery. Dr. Lennerz will present key strategies for implementing an Integrated Diagnostics (IDx) practice, emphasizing the importance of interdisciplinary collaboration, administrative alignment and the integration of real-world data in enhancing patient care and negotiating with payors.
BostonGene's participation in the EFLM Strategic Conference 2024 reflects the company’s dedication to driving innovation in laboratory medicine and integrated diagnostics. The contributions from Dr. Lennerz and BostonGene will be featured in the Clinical Chemistry and Laboratory Medicine journal, highlighting their role in this evolving field.
In addition to his keynote, Dr. Lennerz will be chairing the Integrated Diagnostics Task Group meeting on Sunday, September 22 from 5:00 PM – 7:00 PM. This satellite meeting, attended by both in-person and virtual speakers, will focus on the latest advancements in integrated diagnostics, providing the ideal platform for thought leadership and collaboration.
To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at [email protected]. For more information, visit the EFLM website.
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Latest news
